Treats Wilson's disease. ANDA 211134, held by Msn. Trientine Hydrochloride.
As of Nov 15, 2026, ANDA 211134 (Trientine Hydrochloride), held by Msn, was first approved by FDA on May 22, 2019, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Trientine hydrochloride capsules USP 250 mg is indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine. Clinical experience with trientine hydrochloride capsules USP 250 mg is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient's dose have not been well defined. Trientine hydrochloride capsules USP 250 mg and penicillamine cannot be considered interchangeable. Trientine hydrochloride capsules USP 250 mg should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 22, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Trientine Hydrochloride250MG · capsule;oral | Trientine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
